4
Changes in Ownership
Karyopharm Therapeutics Inc. Filed Acc 0001209191-20-054822
Chief Executive Officer sold 7,500 shares at $14.89 ($111,683)
- Chief Executive Officer acquired 7,500 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kauffman Michael · Chief Executive Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-10-12 | Exercise or conversion : show line 1 in the form | +1,424 | $0.03 | $47 | 757,913 | I |
| 2020-10-12 | Exercise or conversion : show line 2 in the form | +6,076 | $0.03 | $201 | 763,989 | I |
| 2020-10-12 | Sale : show line 3 in the form | −7,500 | $14.89 | $111,683 | 756,489 | I |
| Open-market sales · 7,500 sh · avg $14.89 · $111,683 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2020-10-12 | Exercise or conversion : show line 4 in the form Stock Option (right to buy) | −1,424 | $0.03 | 2020-10-31 | 1,424 | 0 | I |
| 2020-10-12 | Exercise or conversion : show line 5 in the form Stock Option (right to buy) | −6,076 | $0.03 | 2020-10-31 | 6,076 | 0 | I |
Loading xslF345X03/doc4.xml…